infections following anti-bcma bispecific antibodies for multiple myeloma
Published 1 year ago • 208 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
0:41
fcrh5 & gprc5d bispecific antibodies: antigen targets beyond bcma for multiple myeloma
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
2:12
risk of infection and mitigation strategies in patients with myeloma treated with bispecifics
-
6:35
the benefits of bispecific antibodies for treating multiple myeloma
-
1:19
infectious toxicities in patients with multiple myeloma treated with bispecific antibodies
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
1:31
bispecific antibodies in the treatment pipeline for myeloma in the uk
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
5:28
regn5459, a bcma×cd3 bispecific antibody, in r/r multiple myeloma
-
1:38
using bcma-targeting agents in earlier lines of treatment for multiple myeloma
-
2:55
bispecific antibodies for myeloma: highlights from ash 2020
-
1:45
using the available repertoire of bispecific antibodies for treating multiple myeloma
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
4:59
incidence, prevention, and management of infections in multiple myeloma
-
11:06
bites for the treatment of multiple myeloma
-
2:06
improving treatment access with off-the-shelf bispecific antibodies in multiple myeloma
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
1:38
the efficacy of cevostamab in r/r multiple myeloma and the importance of bispecific antibodies
-
1:23
advantages of bispecific antibodies over car-t therapy in lbcl